Abstract
OPINION article Front. Pharmacol., 17 September 2013Sec. Inflammation Pharmacology https://doi.org/10.3389/fphar.2013.00114
Highlights
Telaprevir and boceprevir were approved by the Food and Drug Administration (FDA) in May 2011 for the treatment of hepatitis C virus (HCV) genotype 1 in combination with peginterferon and ribavirin in adult patients with compensated liver disease, including cirrhosis, who have not been treated before or who have failed a previous treatment (Asselah, 2012; Popescu et al, 2012)
(June 2013), patients treated with the protease inhibitors are 87: 58 with telaprevir (51 naive and 7 null responders) and 29 with boceprevir (24 naive and 5 null responders)
This first survey of pharmacoutilization clearly shows that telaprevir is more frequently prescribed than boceprevir
Summary
Telaprevir and boceprevir were approved by the Food and Drug Administration (FDA) in May 2011 for the treatment of HCV genotype 1 in combination with peginterferon and ribavirin (triple therapy) in adult patients with compensated liver disease, including cirrhosis, who have not been treated before or who have failed a previous treatment (Asselah, 2012; Popescu et al, 2012). In Italy, telaprevir and boceprevir were approved in December 2012 after a complicated prescriptive pathway (definition of the AIFA—Agenzia Italiana del FArmaco—register for the intensive monitoring, identification of authorized centers for prescription, definition of dispensing modalities). The first prescriptions of telaprevir and boceprevir in the Local Sanitary Agency (LSA) Naples 3 South Italy (i.e., LSA, NA 3 South, 1.200.000 inhabitants, Campania Region) were done in March 2013.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
